Publikationen, an denen er mitarbeitet Andrea Álvarez Vázquez (8)

2024

  1. A proteomic approach supports the clinical relevance of TAT-Cx43266-283 in glioblastoma

    Translational Research, Vol. 272, pp. 95-110

  2. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models

    Neuro-Oncology, Vol. 26, Núm. 7, pp. 1230-1246

2021

  1. Efecto del péptido antitumoral TAT-Cx43266-283 en células madre neurales en un modelo de glioma in vivo

    VII Jornadas de investigadoras de Castilla y León [Recurso electrónico]: la aventura de la ciencia y la tecnología (Fundación 3CIN), pp. 84

  2. Erratum to “Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266-283” [EBioMedicine 62, December 2020] DOI: https://doi.org/10.1016/j.ebiom.2020.103134 (EBioMedicine (2020) 62, (S2352396420305107), (10.1016/j.ebiom.2020.103134))

    EBioMedicine

  3. Erratum: Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo (Neuro-Oncology DOI: 10.1093/neuonc/noz243)

    Neuro-Oncology

  4. Péptidos penetrantes para atacar al glioma y su microambiente

    VII Jornadas de investigadoras de Castilla y León [Recurso electrónico]: la aventura de la ciencia y la tecnología (Fundación 3CIN), pp. 50

2020

  1. Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo

    Neuro-Oncology, Vol. 22, Núm. 4, pp. 493-504

  2. Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266-283

    EBioMedicine, Vol. 62